A 52-year-old man with chronic obstructive pulmonary disease (COPD) exacerbation is admitted and started on intravenous methylprednisolone 500 mg once daily. After 3 days of therapy, he develops severe hypokalemia (serum K⁺ = 2.8 mEq/L) and hypertension (BP 165/95 mmHg). His blood glucose is 240 mg/dL. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient is experiencing **mineralocorticoid excess syndrome** — a constellation of adverse effects from high-dose corticosteroid therapy: hypokalemia, hypertension, and hyperglycemia. These are predictable dose-dependent side effects requiring intervention. ## Mineralocorticoid Effects of Corticosteroids **Key Point:** All corticosteroids have some mineralocorticoid activity. High-dose, long-acting corticosteroids (like methylprednisolone) cause: - **Sodium retention** → volume expansion → hypertension - **Potassium wasting** → hypokalemia (via increased urinary K⁺ excretion in the collecting duct) - **Hydrogen ion wasting** → metabolic alkalosis - **Hyperglycemia** → impaired glucose tolerance and insulin resistance | Corticosteroid | Glucocorticoid Activity | Mineralocorticoid Activity | Duration | |---|---|---|---| | Hydrocortisone | 1 | 1 | Short (8–12 hrs) | | Prednisolone | 4 | 0.8 | Intermediate (12–36 hrs) | | Methylprednisolone | 5 | ~0 | Intermediate (12–36 hrs) | | Dexamethasone | 30 | ~0 | Long (36–72 hrs) | | Fludrocortisone | 15 | 150 | Long | **High-Yield:** Methylprednisolone has minimal mineralocorticoid activity, yet at high IV doses (500 mg daily), it still causes significant potassium wasting and sodium retention due to the sheer magnitude of glucocorticoid effect. ## Rationale for Correct Answer The most appropriate next step is to: 1. **Reduce the methylprednisolone dose** — High-dose IV therapy (500 mg daily) is typically appropriate only for 3–5 days in acute exacerbations. Continuing at this dose increases adverse effects without additional benefit. 2. **Switch to oral prednisolone** — Oral corticosteroids are more practical for continued therapy and allow easier dose titration. 3. **Supplement potassium** — Hypokalemia (K⁺ = 2.8 mEq/L) is severe and symptomatic; potassium replacement is essential to prevent cardiac arrhythmias. 4. **Monitor electrolytes closely** — Serial measurements of K⁺, Na⁺, and HCO₃⁻ are needed to guide further management. **Clinical Pearl:** Severe hypokalemia (K⁺ < 3.0 mEq/L) increases the risk of cardiac arrhythmias, especially in patients with underlying cardiac disease or those on other medications affecting potassium. Urgent correction is needed. ## Why This Approach Is Superior ```mermaid flowchart TD A[High-dose IV methylprednisolone 500 mg daily]:::outcome --> B{Day 3-5 of therapy?}:::decision B -->|Yes| C[Taper to oral prednisolone]:::action B -->|No| D[Continue IV therapy] C --> E[Reduce dose based on clinical response]:::action E --> F[Supplement K⁺ if K+ < 3.5 mEq/L]:::action F --> G[Monitor K+, Na+, glucose, BP]:::action G --> H[Reassess in 24-48 hrs]:::decision H -->|Improved| I[Continue oral prednisolone taper]:::action H -->|Worsening| J[Consider mineralocorticoid antagonist]:::action ``` ## Addressing Each Adverse Effect | Adverse Effect | Mechanism | Management | |---|---|---| | Hypokalemia (K⁺ = 2.8) | Increased renal K⁺ excretion | Potassium supplementation (IV KCl if severe); target K⁺ > 3.5 mEq/L | | Hypertension | Sodium retention, volume expansion | Reduce corticosteroid dose; diuretic if needed | | Hyperglycemia | Impaired insulin secretion, increased gluconeogenesis | Monitor glucose; insulin if persistent | **Key Point:** Spironolactone (a mineralocorticoid antagonist) is NOT the first-line approach here because the primary issue is **excessive corticosteroid dose**, not primary hyperaldosteronism. Reducing the dose is more effective and avoids additional medication.